Literature DB >> 6421500

Increased cancericidal activity of PTT.119, a new synthetic bis-(2-chloroethyl)amino-L-phenylalanine derivative with carrier amino acids. I. In vitro cytotoxicity.

M J Yagi, J G Bekesi, M D Daniel, J F Holland, A De Barbieri.   

Abstract

A new synthetic tripeptide (p-F-Phe-m-bis-(2-chloroethyl)amino-Phe-Met ethoxy HCl), PTT.119, was demonstrated to have significant cancericidal activity against seven in vitro tumor cell lines of different origins and etiologies and against primary human AMML, ALL, and hairy cell leukemias. Viabilities of each murine tumor and rabbit, marmoset, and human leukemia and lymphoma line were significantly reduced by treatment with 1-50 micrograms PTT.119 in media containing serum. Continuous 24-h exposure or pulse treatment as short as 15 and 30 min with the tripeptide resulted in irreversible damage to the tumor cells. Under identical treatment conditions, freshly isolated human leukemic cells, particularly ALL lymphoblasts, were even more susceptible to PTT.119 than any of the tested tumor cell models. Examination of the parameters of PTT.119 activity revealed that reductions of tumor cell survival were dependent on the concentration of the tripeptide. Prolongation of PTT.119 exposure from 15 min to 24 h increased the rates of tumor cell death but did not proportionally reduce the numbers of surviving cells. Assessment of tumor cell viabilities for 5 consecutive days following pulse exposure to PTT.119 demonstrated increasing reductions in tumor cell survival, which were greatest 5 days after treatment of PTT.119 was compared with its three parental components either as individual agents or as a mixture. Both the alkylator moiety, m-sarcolysin (m.L.SL) alone or together with p-fluoro-phenylalanine and L-methionine ethoxy HCl, and L-PAM (L-phenylalanine and L-methionine ethoxy HCl, and L-PAM (L-phenylalanine mustard), the p-isomer of m.L.SL, were 1,5- to 3-fold less cytotoxic to L1210 leukemia and MJY-alpha mammary tumor cells than PTT.119. Covalent linkage of the amino acid residues to m.L.SL yielded a molecule with greatly augmented cancericidal activity capable of acting against a broad spectrum of tumor cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6421500     DOI: 10.1007/bf00254592

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  22 in total

1.  Studies on the anti-tumour activity of p-di-(2-chloroethyl) aminophenylalanine (sarcolysine).

Authors:  L F LARIONOV; E N SHKODINSKAJA; V I TROOSHEIKINA; A S KHOKHLOV; O S VASINA; M A NOVIKOVA
Journal:  Lancet       Date:  1955-07-23       Impact factor: 79.321

2.  Peptichemio in the therapy of malignancies (phase-I-study). The evaluation committee.

Authors:  N Gingold; E Pittermann; A Stacher
Journal:  Int J Clin Pharmacol       Date:  1974-10

3.  Synthesis and screening of substances acting by alkylation and metabolic inhibition.

Authors:  A De Barbieri
Journal:  Acta Genet Med Gemellol (Roma)       Date:  1968-01

4.  Cytotoxic effects of peptichemio on synchronized EUE cells.

Authors:  R Di Lernia; G Della Valle; A De Barbieri; O Temelcou; L De Carli
Journal:  Biochem Exp Biol       Date:  1978

5.  Epstein-Barr virus (EBV)-lymphoid cell interactions. I. Quantification of EBV particles required for the membrane immunofluorescence assay and the comparative expression of EBV receptors on different human B, T and null cell lines.

Authors:  P Patel; J Menezes
Journal:  J Gen Virol       Date:  1981-03       Impact factor: 3.891

6.  Carrier-dependent and carrier-independent transport of anti-cancer alkylating agents.

Authors:  J E Byfield; P M Calabro-Jones
Journal:  Nature       Date:  1981-11-19       Impact factor: 49.962

Review 7.  L-phenylalanine mustard (L-PAM): the first 25 years.

Authors:  R L Furner; R K Brown
Journal:  Cancer Treat Rep       Date:  1980 Apr-May

8.  Rapid detection of mycoplasma-infected cell cultures.

Authors:  G J Todaro; S A Aaronson; E Rands
Journal:  Exp Cell Res       Date:  1971-03       Impact factor: 3.905

9.  A phase II study of peptichemio in advanced breast cancer.

Authors:  V Hug; G N Hortobagyi; A U Buzdar; G R Blumenschein; W Grose; M A Burgess; G P Bodey
Journal:  Cancer       Date:  1980-05-15       Impact factor: 6.860

10.  Effect of peptichemio exposure on DNA synthesis in a mammalian cell system in vitro.

Authors:  O Djordjević; L Kostić; G Astaldi
Journal:  Tumori       Date:  1975 Sep-Oct
View more
  10 in total

1.  Phase II cooperative study with a new alkylating drug, PTT-119, in the treatment of non-Hodgkin's lymphomas.

Authors:  F Gherlinzoni; P Mazza; P L Zinzani; S Tura; F Lanza; G Castoldi; G Bellesi; P L Rossi Ferrini; L Mangoni; V Rizzoli
Journal:  Blut       Date:  1990-03

2.  Sensitivity of chronic myeloid leukemia hemopoietic progenitors to PTT-119 in combination with human recombinant interferon alpha and gamma.

Authors:  G Visani; R M Lemoli; P Tosi; F Verlicchi; B Gamberi; A R Cenacchi; R Colombini; M Fogli; D Russo; E Zuffa
Journal:  Blut       Date:  1990-05

3.  Phase I study of beta-alanyl-melphalan as a potent anticancer drug.

Authors:  B L Tsay; L Wolfinbarger
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Evidence for increased intracellular transport of m-sarcolysine (alkylating moiety) when combined with two amino acid analogs (PTT-119).

Authors:  F Verlicchi; S Boschi; G Visani; A Guidi; P Tosi; M Cavo; S Tura
Journal:  Blut       Date:  1990-11

5.  Evaluation of p-F-Phe-m-bis-(2-chloroethyl)amino-L-Phe-Met-ethoxy HCl against transplantable and spontaneous murine neoplasia.

Authors:  M J Yagi; J G Bekesi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Increased cancericidal activity of PTT.119; a new synthetic bis-(2-chloroethyl)amino-L-phenylalanine derivative with carrier amino acids. II. In vivo bioassay.

Authors:  M J Yagi; M Zanjani; J F Holland; J G Bekesi
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

7.  Antitumor action of N-(2-chloroethyl)-N-nitrosocarbamoyl derivatives of biologically active polypeptide hormone fragments.

Authors:  A Jeney; L Kopper; P Nagy; K Lapis; H Süli-Vargha; K Medzihradszky
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

8.  In vitro studies of 2,4-dihydroxyphenylalanine, a prodrug targeted against malignant melanoma cells.

Authors:  M E Morrison; M J Yagi; G Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

9.  Evaluation of 3-(p-fluorophenyl)-L-alanyl-3-[m-bis-(2-chloroethyl) aminophenyl]-L-alanyl-L-methionine ethyl ester HCl (PTT.119) against xenografts of human rhabdomyosarcoma.

Authors:  P J Houghton; R Tharp; J A Houghton; J F Holland; J G Bekesi
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

10.  Comparison of the cytotoxic activity of melphalan with L-prolyl-m-L-sarcolysyl-L-p-fluorophenylalanine in human tumour cell lines and primary cultures of tumour cells from patients.

Authors:  R Larsson; S Dhar; H Ehrsson; P Nygren; R Lewensohn
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.